381 related articles for article (PubMed ID: 27044261)
1. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
2. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
3. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
[TBL] [Abstract][Full Text] [Related]
4. High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation.
Tian P; Wang Y; Wang W; Li Y; Wang K; Cheng X; Tang Y; Han-Zhang H; Ye J; Chuai S; Li W
Lung Cancer; 2018 Oct; 124():205-210. PubMed ID: 30268462
[TBL] [Abstract][Full Text] [Related]
5. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
Liu Z; Gao W
Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
[TBL] [Abstract][Full Text] [Related]
6. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
7. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
[TBL] [Abstract][Full Text] [Related]
8. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
Remon J; Planchard D
Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
[TBL] [Abstract][Full Text] [Related]
9. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment.
Chia PL; Do H; Morey A; Mitchell P; Dobrovic A; John T
Lung Cancer; 2016 Aug; 98():29-32. PubMed ID: 27393503
[TBL] [Abstract][Full Text] [Related]
10. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
Xu J; Zhu GY; Cao D; Pan H; Li YW
Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
[TBL] [Abstract][Full Text] [Related]
11. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
12. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
[TBL] [Abstract][Full Text] [Related]
13. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
Tong M; Gao M; Xu Y; Fu L; Li Y; Bao X; Fu H; Quan H; Lou L
Cancer Sci; 2019 Nov; 110(11):3584-3594. PubMed ID: 31446643
[TBL] [Abstract][Full Text] [Related]
14. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
15. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
16. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.
Ku BM; Choi MK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
PLoS One; 2018; 13(4):e0194730. PubMed ID: 29641535
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
[TBL] [Abstract][Full Text] [Related]
19. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
Finlay MR; Anderton M; Ashton S; Ballard P; Bethel PA; Box MR; Bradbury RH; Brown SJ; Butterworth S; Campbell A; Chorley C; Colclough N; Cross DA; Currie GS; Grist M; Hassall L; Hill GB; James D; James M; Kemmitt P; Klinowska T; Lamont G; Lamont SG; Martin N; McFarland HL; Mellor MJ; Orme JP; Perkins D; Perkins P; Richmond G; Smith P; Ward RA; Waring MJ; Whittaker D; Wells S; Wrigley GL
J Med Chem; 2014 Oct; 57(20):8249-67. PubMed ID: 25271963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
